Additionally, an increase in SLC2A2 has been observed due astrocyte activation in AD, while a reduction in SLC1A2, particularly within the hippocampal and prefrontal cortex regions, has been noted in the advanced stages of AD and during the progression of mild cognitive impairment [73,74,75,76,77,78,79,80]. Here, SLC1A2 is linked to Alzheimer disease.